Movement Alert｜3SBio Falls 5.62% in Regular Trading, Biotech Sector Pulls Back After ASCO Catalyst

Market Focus06-02

On June 2, 3SBio fell 5.62% in regular trading, trading at HK$17.12/share, with trading volume of HK$133 million. The decline follows two consecutive sessions of strong gains driven by ASCO Annual Meeting catalysts, with the broader biotech sector now experiencing broad-based profit-taking.

During the ASCO conference, 3SBio's core pipeline candidate SSGJ-707, a PD-1/VEGF bispecific antibody, had two Phase II clinical studies selected for presentation, with one receiving rapid oral report status. Published data showed a confirmed objective response rate of 67.6% and median progression-free survival of 12.4 months in advanced non-small cell lung cancer, which had propelled the stock up approximately 7.25% on June 1 alone.

The pullback reflects sector-wide profit-taking pressure following the concentrated release of ASCO catalysts. Within the Biotechnology sector, AKESO fell 7.33%, SKB Bio fell 7.63%, Innovent Bio fell 4.20%, BeiGene fell 3.56%, and Remegen fell 4.02%, indicating broad selling across the space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176280574?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176280574","market":"hk","top_or_hot":-1,"title":"Movement Alert｜3SBio Falls 5.62% in Regular Trading, Biotech Sector Pulls Back After ASCO Catalyst","media":"Market Focus","content":"<p><p>On June 2, 3SBio fell 5.62% in regular trading, trading at HK$17.12/share, with trading volume of HK$133 million. The decline follows two consecutive sessions of strong gains driven by ASCO Annual Meeting catalysts, with the broader biotech sector now experiencing broad-based profit-taking.</p><p>During the ASCO conference, 3SBio's core pipeline candidate SSGJ-707, a PD-1/VEGF bispecific antibody, had two Phase II clinical studies selected for presentation, with one receiving rapid oral report status. Published data showed a confirmed objective response rate of 67.6% and median progression-free survival of 12.4 months in advanced non-small cell lung cancer, which had propelled the stock up approximately 7.25% on June 1 alone.</p><p>The pullback reflects sector-wide profit-taking pressure following the concentrated release of ASCO catalysts. Within the Biotechnology sector, AKESO fell 7.33%, SKB Bio fell 7.63%, Innovent Bio fell 4.20%, BeiGene fell 3.56%, and Remegen fell 4.02%, indicating broad selling across the space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜3SBio Falls 5.62% in Regular Trading, Biotech Sector Pulls Back After ASCO Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜3SBio Falls 5.62% in Regular Trading, Biotech Sector Pulls Back After ASCO Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-02 09:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 2, 3SBio fell 5.62% in regular trading, trading at HK$17.12/share, with trading volume of HK$133 million. The decline follows two consecutive sessions of strong gains driven by ASCO Annual Meeting catalysts, with the broader biotech sector now experiencing broad-based profit-taking.</p><p>During the ASCO conference, 3SBio's core pipeline candidate SSGJ-707, a PD-1/VEGF bispecific antibody, had two Phase II clinical studies selected for presentation, with one receiving rapid oral report status. Published data showed a confirmed objective response rate of 67.6% and median progression-free survival of 12.4 months in advanced non-small cell lung cancer, which had propelled the stock up approximately 7.25% on June 1 alone.</p><p>The pullback reflects sector-wide profit-taking pressure following the concentrated release of ASCO catalysts. Within the Biotechnology sector, AKESO fell 7.33%, SKB Bio fell 7.63%, Innovent Bio fell 4.20%, BeiGene fell 3.56%, and Remegen fell 4.02%, indicating broad selling across the space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1176280574","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176280574","pubTimestamp":1780364527,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 2, 3SBio fell 5.62% in regular trading, trading at HK$17.12/share, with trading volume of HK$133 million. The decline follows two consecutive sessions of strong gains driven by ASCO Annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"动向提示|三生制药常规交易跌5.62%生物科技板块受ASCO催化剂影响回调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"On June 2, 3SBio fell 5.62% in regular trading, trading at HK$17.12/share, with trading volume of HK$133 million. The decline follows two consecutive sessions of strong gains driven by ASCO Annual Meeting catalysts, with the broader biotech sector now experiencing broad-based profit-taking.During the ASCO conference, 3SBio's core pipeline candidate SSGJ-707, a PD-1/VEGF bispecific antibody, had two Phase II clinical studies selected for presentation, with one receiving rapid oral report status. Published data showed a confirmed objective response rate of 67.6% and median progression-free survival of 12.4 months in advanced non-small cell lung cancer, which had propelled the stock up approximately 7.25% on June 1 alone.The pullback reflects sector-wide profit-taking pressure following the concentrated release of ASCO catalysts. Within the Biotechnology sector, AKESO fell 7.33%, SKB Bio fell 7.63%, Innovent Bio fell 4.20%, BeiGene fell 3.56%, and Remegen fell 4.02%, indicating broad selling across the space.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176280574","isCrawlerRequest":true}